Ascorbic acid reduces Ropivacaine-induced myotoxicity in cultured human osteoporotic skeletal muscle cells
Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a pote...
Saved in:
| Published in | BMC musculoskeletal disorders Vol. 24; no. 1; pp. 576 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
15.07.2023
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts.
Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers.
A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment.
Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. |
|---|---|
| AbstractList | Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts.
Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers.
A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment.
Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts.BACKGROUNDOsteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts.Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers.METHODSPrimary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers.A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment.RESULTSA dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment.Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture.CONCLUSIONSOur findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. BackgroundOsteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts.MethodsPrimary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers.ResultsA dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment.ConclusionsOur findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts. Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers. A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment. Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. Abstract Background Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts. Methods Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers. Results A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment. Conclusions Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. Background Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts. Methods Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers. Results A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment. Conclusions Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture. Keywords: Local anesthesia, Skeletal muscle, Myotoxicity, Oxidative stress, Myogenesis |
| ArticleNumber | 576 |
| Audience | Academic |
| Author | Savino, Luca Gasbarra, Elena Greggi, Chiara Tarantino, Umberto Scioli, Maria Giovanna Piccirilli, Eleonora Coniglione, Filadelfo Fiorelli, Elena Orlandi, Augusto Evangelista, Luca Ferlosio, Amedeo Iundusi, Riccardo |
| Author_xml | – sequence: 1 givenname: Maria Giovanna surname: Scioli fullname: Scioli, Maria Giovanna – sequence: 2 givenname: Filadelfo surname: Coniglione fullname: Coniglione, Filadelfo – sequence: 3 givenname: Chiara surname: Greggi fullname: Greggi, Chiara – sequence: 4 givenname: Luca surname: Evangelista fullname: Evangelista, Luca – sequence: 5 givenname: Elena surname: Fiorelli fullname: Fiorelli, Elena – sequence: 6 givenname: Luca surname: Savino fullname: Savino, Luca – sequence: 7 givenname: Amedeo surname: Ferlosio fullname: Ferlosio, Amedeo – sequence: 8 givenname: Eleonora surname: Piccirilli fullname: Piccirilli, Eleonora – sequence: 9 givenname: Elena surname: Gasbarra fullname: Gasbarra, Elena – sequence: 10 givenname: Riccardo surname: Iundusi fullname: Iundusi, Riccardo – sequence: 11 givenname: Umberto surname: Tarantino fullname: Tarantino, Umberto – sequence: 12 givenname: Augusto surname: Orlandi fullname: Orlandi, Augusto |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37454045$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhU1JaR7tH-iiGLrpxqneklclhD4CgUJp10KSryea2tJUskPm31eeSdNMKEULiaPvHulezml1FGKAqnqN0TnGSrzPmKgWN4jQBgmJSMOfVSeYSdwQJtnRo_NxdZrzGiEsFW1fVMdUMs4Q4yfV-iK7mKx3tXG-qxN0s4Ncf4sbf2uc8QEaHxatq8dtnOKdd37a1j7Ubh6mufD1zTyaUMc8QdzEFKfilX_CAJMZ6nHOboDawTDkl9Xz3gwZXt3vZ9WPTx-_X35prr9-vrq8uG4cF2xqLLTMcAJtjxiBnjIiibPCYd4V1VDSkg6wUUi0iAljrXNClkG0BpwgwtGz6mrv20Wz1pvkR5O2Ohqvd0JMK21S-eUA2lpiGQPmKC4bVVa1AvUgJeJAe8uL14e912a2I3QOwpTMcGB6eBP8jV7FW40R5YhwURze3Tuk-GuGPOnR52UeJkCcsyaKKsKxwKygb5-g6zinUGa1o6RUSuG_1MqUDnzoY3nYLab6QnJJWlrAQp3_gyqrg9G7kqPeF_2g4M3jTh9a_BOVApA94FLMOUH_gGCklzzqfR51yaPe5VEvRepJUYmPmXxcpuWH_5X-Bo8J5MM |
| CitedBy_id | crossref_primary_10_2174_0115734137281377240103062220 crossref_primary_10_1093_nutrit_nuae214 |
| Cites_doi | 10.3390/ijerph16071228 10.1155/2014/372021 10.1002/jcp.24667 10.1097/ALN.0b013e3181e4f4ec 10.2106/JBJS.H.01847 10.3390/antiox11040755 10.1007/s40520-013-0074-1 10.1016/j.atherosclerosis.2012.07.016 10.2174/13816128113196660690 10.1007/s00540-017-2441-0 10.1002/term.2030 10.1177/1759720X221138354 10.1038/s41598-019-38536-4 10.1213/ANE.0b013e31829e4197 10.1097/MCO.0000000000000230 10.1007/s10974-015-9438-9 10.1016/j.ceca.2016.02.010 10.1002/term.2139 10.1007/s11739-018-1874-2 10.2147/JPR.S398329 10.1002/tox.22327 10.1155/2019/1704650 10.1186/s12935-015-0229-6 10.1097/00000542-200209000-00026 10.1177/0363546514550991 10.1007/s00223-023-01093-0 10.3389/fphar.2022.929448 10.1016/j.rapm.2004.02.008 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7RV 7TK 7TS 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12891-023-06702-5 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Physical Education Index ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database ProQuest Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Physical Education Index ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1471-2474 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_bb2b44e4c3144e38b8960fe7705e3fb5 PMC10350256 A757293778 37454045 10_1186_s12891_023_06702_5 |
| Genre | Journal Article |
| GeographicLocations | Italy United States--US California |
| GeographicLocations_xml | – name: Italy – name: United States--US – name: California |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QP 7TK 7TS 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c564t-be94a52e9f042ef34272cb6c15d52ea3292de1a8069046abbcc672899aec626c3 |
| IEDL.DBID | M48 |
| ISSN | 1471-2474 |
| IngestDate | Wed Aug 27 01:25:28 EDT 2025 Thu Aug 21 18:36:44 EDT 2025 Fri Jul 11 02:14:41 EDT 2025 Sat Jul 26 00:19:07 EDT 2025 Tue Jun 17 21:31:49 EDT 2025 Tue Jun 10 21:24:04 EDT 2025 Wed Feb 19 02:22:54 EST 2025 Tue Jul 01 01:09:26 EDT 2025 Thu Apr 24 22:57:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Oxidative stress Myogenesis Myotoxicity Skeletal muscle Local anesthesia |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c564t-be94a52e9f042ef34272cb6c15d52ea3292de1a8069046abbcc672899aec626c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2838778881?pq-origsite=%requestingapplication% |
| PMID | 37454045 |
| PQID | 2838778881 |
| PQPubID | 44767 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bb2b44e4c3144e38b8960fe7705e3fb5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10350256 proquest_miscellaneous_2838251614 proquest_journals_2838778881 gale_infotracmisc_A757293778 gale_infotracacademiconefile_A757293778 pubmed_primary_37454045 crossref_primary_10_1186_s12891_023_06702_5 crossref_citationtrail_10_1186_s12891_023_06702_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-07-15 |
| PublicationDateYYYYMMDD | 2023-07-15 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC musculoskeletal disorders |
| PublicationTitleAlternate | BMC Musculoskelet Disord |
| PublicationYear | 2023 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | W Zink (6702_CR16) 2004; 29 A Ferlosio (6702_CR21) 2012; 224 C-M Sung (6702_CR28) 2014; 42 M Celi (6702_CR18) 2013; 25 6702_CR26 6702_CR24 Y Chen (6702_CR25) 2019; 47 Y Madokoro (6702_CR17) 2022; 13 MG Scioli (6702_CR20) 2014; 229 MG Scioli (6702_CR22) 2017; 11 U Tarantino (6702_CR2) 2014; 2014 K Ikeda (6702_CR30) 2017; 11 BOS Duran (6702_CR29) 2019; 9 K Kido (6702_CR19) 2018; 32 A Shimonty (6702_CR5) 2023 J-Y Reginster (6702_CR27) 2016; 19 O Galbes (6702_CR14) 2010; 113 A Espinosa (6702_CR10) 2016; 60 T Metterlein (6702_CR12) 2015; 15 CD Pandya (6702_CR7) 2019; 2019 M Scimeca (6702_CR3) 2017; 32 6702_CR8 S Lee (6702_CR23) 2011; 4 W Zink (6702_CR13) 2002; 97 M Kozakowska (6702_CR9) 2015; 36 K Zhang (6702_CR15) 2023; 16 P Hofmann (6702_CR11) 2013; 117 L Ferrucci (6702_CR6) 2014; 20 U Tarantino (6702_CR4) 2022; 14 R Nuti (6702_CR1) 2019; 14 |
| References_xml | – ident: 6702_CR26 doi: 10.3390/ijerph16071228 – volume: 4 start-page: 351 year: 2011 ident: 6702_CR23 publication-title: Mol Med Rep – volume: 2014 start-page: 372021 year: 2014 ident: 6702_CR2 publication-title: Int J Endocrinol doi: 10.1155/2014/372021 – volume: 229 start-page: 2077 year: 2014 ident: 6702_CR20 publication-title: J Cell Physiol doi: 10.1002/jcp.24667 – volume: 113 start-page: 560 year: 2010 ident: 6702_CR14 publication-title: Anesthesiology doi: 10.1097/ALN.0b013e3181e4f4ec – ident: 6702_CR24 doi: 10.2106/JBJS.H.01847 – ident: 6702_CR8 doi: 10.3390/antiox11040755 – volume: 25 start-page: 47 issue: Suppl 1 year: 2013 ident: 6702_CR18 publication-title: Aging Clin Exp Res doi: 10.1007/s40520-013-0074-1 – volume: 224 start-page: 51 year: 2012 ident: 6702_CR21 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2012.07.016 – volume: 20 start-page: 3178 year: 2014 ident: 6702_CR6 publication-title: Curr Pharm Des doi: 10.2174/13816128113196660690 – volume: 32 start-page: 120 year: 2018 ident: 6702_CR19 publication-title: J Anesth doi: 10.1007/s00540-017-2441-0 – volume: 11 start-page: 1322 year: 2017 ident: 6702_CR30 publication-title: J Tissue Eng Regen Med doi: 10.1002/term.2030 – volume: 14 start-page: 1759720X2211383 year: 2022 ident: 6702_CR4 publication-title: Ther Adv Musculoskelet Dis doi: 10.1177/1759720X221138354 – volume: 9 start-page: 2229 year: 2019 ident: 6702_CR29 publication-title: Sci Rep doi: 10.1038/s41598-019-38536-4 – volume: 117 start-page: 634 year: 2013 ident: 6702_CR11 publication-title: Anesth Analg doi: 10.1213/ANE.0b013e31829e4197 – volume: 19 start-page: 31 year: 2016 ident: 6702_CR27 publication-title: Curr Opin Clin Nutr Metab Care doi: 10.1097/MCO.0000000000000230 – volume: 36 start-page: 377 year: 2015 ident: 6702_CR9 publication-title: J Muscle Res Cell Motil doi: 10.1007/s10974-015-9438-9 – volume: 60 start-page: 172 year: 2016 ident: 6702_CR10 publication-title: Cell Calcium doi: 10.1016/j.ceca.2016.02.010 – volume: 11 start-page: 2398 year: 2017 ident: 6702_CR22 publication-title: J Tissue Eng Regen Med doi: 10.1002/term.2139 – volume: 14 start-page: 85 year: 2019 ident: 6702_CR1 publication-title: Intern Emerg Med doi: 10.1007/s11739-018-1874-2 – volume: 16 start-page: 611 year: 2023 ident: 6702_CR15 publication-title: J Pain Res doi: 10.2147/JPR.S398329 – volume: 32 start-page: 1333 year: 2017 ident: 6702_CR3 publication-title: Environ Toxicol doi: 10.1002/tox.22327 – volume: 2019 start-page: 1704650 year: 2019 ident: 6702_CR7 publication-title: Oxid Med Cell Longev doi: 10.1155/2019/1704650 – volume: 15 start-page: 75 year: 2015 ident: 6702_CR12 publication-title: Cancer Cell Int doi: 10.1186/s12935-015-0229-6 – volume: 47 start-page: 1788 year: 2019 ident: 6702_CR25 publication-title: Biotechnol – volume: 97 start-page: 710 year: 2002 ident: 6702_CR13 publication-title: Anesthesiology doi: 10.1097/00000542-200209000-00026 – volume: 42 start-page: 2888 year: 2014 ident: 6702_CR28 publication-title: Am J Sports Med doi: 10.1177/0363546514550991 – year: 2023 ident: 6702_CR5 publication-title: Calcif Tissue Int doi: 10.1007/s00223-023-01093-0 – volume: 13 start-page: 929448 year: 2022 ident: 6702_CR17 publication-title: Front Pharmacol doi: 10.3389/fphar.2022.929448 – volume: 29 start-page: 333 year: 2004 ident: 6702_CR16 publication-title: Reg Anesth Pain Med doi: 10.1016/j.rapm.2004.02.008 |
| SSID | ssj0017839 |
| Score | 2.376487 |
| Snippet | Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable... Background Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a... BackgroundOsteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a... Abstract Background Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 576 |
| SubjectTerms | Analgesics Anesthesia Antibodies Apoptosis Ascorbic acid Ascorbic Acid - metabolism Ascorbic Acid - pharmacology Autophagy Biomechanics Bone density Bone mass Bone surgery Care and treatment Cell Differentiation - physiology Cell viability Cells, Cultured Complications and side effects Cytotoxicity Diagnosis Dosage and administration Experiments Fractures Gene expression Health care Hip Humans Joint surgery Local anesthesia Medical examination Muscle Development - physiology Muscle Fibers, Skeletal Muscle, Skeletal - physiology Muscles Musculoskeletal diseases Musculoskeletal system Myoblasts MyoD protein Myogenesis Myostatin Myotoxicity Myotoxicity - metabolism Myotubes Neuromuscular diseases NOX4 protein Osteoporosis Oxidants Oxidative stress Pain Patients Propofol Reactive Oxygen Species - metabolism Recovery of function Risk factors Ropivacaine Skeletal muscle Vitamin C |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB6hBRkJwQFF3fi9xwVRVRw4ICr1ZtnORATYpGp2Ef33zDjZ1UZIcOE6dhTbM_Z8Y48_M_YqgdKgHZSgY8AABXTpUsTAtYEKjIUFiinb4pO5uFQfr_TVwVNflBM20gOPA3cWo4hKgUoSoT9IFx1i7gasXWiQTczspejzdsHUdH5g0e_vrsg4czbgKkwZPoJeMrC4BuiZG8ps_X-uyQdOaZ4weeCBzu-zexN05KuxyQ_YHegesuNVh2Hz-pa_5jmZM--SH7NvqwHDytgmHlJb8xsiaIWBf-6v258hBYSWJQbjKKv5-rbf9L_ahHCctx0fqThQnl_v43QHpEeM3uNP-fAdnRSidb7eDtgETrv-wyN2ef7hy_uLcnpWoUzaqE0ZYamCFrBscMJCI5WwAtWTKl2jNEixFDVUwRGHsTIhxpSMpbgsQMLwJ8nH7KjrO3jKuFrUICoZVWqMsljVmFq5Ri5rp1VUtmDVbpR9mjjH6emLHz7HHs74UTMeNeOzZrwu2Nv9N9cj48Zfa78j5e1rElt2FqAN-cmG_L9sqGBvSPWe5jQ2L4XpagJ2ktix_MpqjEGkta5gp7OaOBfTvHhnPH5aCwaPAM5Z2mmoCvZyX0xfUn5bB_12rINIE7FSwZ6MtrbvkrTEkqiwlW5mhbM-z0u69mtmCq_o3BhB7bP_MUon7K7IM8iWlT5lR5ubLTxHRLaJL_Lk-w0G6zSD priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection (NC LIVE) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZguXBBwPIILMhICA4o2iZ-9oQKYrXiwAGxUm-W7UwgQJPStIj998w4adkIaa_2pLUzz88ZzzD2MoJUoCzkoIJHgAIqtzEgcK2hAG1ghsOUbfFJn1_Ij0u1HA_c-jGtcm8Tk6Guukhn5KfoBq0hvFa8Xf_KqWsUfV0dW2jcZLeodBlJtVkeAFdh0PvvL8pYfdqjLaY8n5L6GRi0BGrijFLN_v8t8xXXNE2bvOKHzu6yO2MAyRcDx--xG9DeZ8eLFsHz6pK_4imlM52VH7Pvix7BZWgi97Gp-IbKtELPP3fr5rePHgPMHCE5jlV8ddltuz9NxKCcNy0fCnLgeOrhx-kmSIeReod_yvsf6KowZuerXY9L4HT23z9gF2cfvrw_z8fmCnlUWm7zAHPpVQnzGtUWaiFLUyKTYqEqHPWinJcVFN5SJWOpfQgxakPozENEEBTFQ3bUdi08ZlzOKigLEWSstTRIqnUlbS3mlVUySJOxYv-WXRwrj1MDjJ8uIRCr3cAZh5xxiTNOZezN4Zn1UHfjWup3xLwDJdXMTgPd5qsbVdCFUAYpQUaBIBKEDRbRWw3GzBSIOuCPvCbWO9JsXF704wUF3CTVyHILoxCJCBTCjJ1MKFEj43R6LzxutAi9-ye_GXtxmKYnKcuthW430GC8iRFTxh4NsnbYkjBUK1HiKu1ECid7ns60zbdUL7ygr8cY2j65fl1P2e0y6YbJC3XCjrabHTzDiGsbnie1-gvVGiwP priority: 102 providerName: ProQuest |
| Title | Ascorbic acid reduces Ropivacaine-induced myotoxicity in cultured human osteoporotic skeletal muscle cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37454045 https://www.proquest.com/docview/2838778881 https://www.proquest.com/docview/2838251614 https://pubmed.ncbi.nlm.nih.gov/PMC10350256 https://doaj.org/article/bb2b44e4c3144e38b8960fe7705e3fb5 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf28cILAsZHYFRGQvCAAk1ix-4DQh3aNCExoYlKfbNi5zICazKaFq3_PXdOUhYxIV7tc2L77uz72ec7xl46EBKkhhCkzRCggAy1swhcC4ggVTDGYvK2OEtPZ-LTXM53WJ_uqJvA5lZoR_mkZsvLt9c_Nx9Q4d97hdfpuwbXWPLfiSlPgUINl7tsH3cmRRkNPos_twpK-8xiES7IYSyU6B_R3PqNwUbl4_n_vWrf2LaGLpU39qiTe-xuZ1zyaSsN99kOVA_YwbRCYL3Y8Ffcu3v6c_QD9n3aIPC0peOZK3O-pBCu0PDz-qr8lbkMjc8Q4TqW5XyxqVf1denQYOdlxdtgHVju8_txeiVS4wTW-FPe_MBtDKeSL9YNdoHTvUDzkM1Ojr9-PA27xAuhk6lYhRYmIpMxTApUaSgSEasYGegimWNplsSTOIco0xTlWKSZtc6lipBbBg4Bkksesb2qruAJ42KcQxwlVrgiFQpJ0zQXukgmuZbCChWwqJ9l47qo5JQc49J4dKJT03LGIGeM54yRAXuzbXPVxuT4J_URMW9LSfG0fUG9vDCdehprYysECJcgwIREW43IrgClxhKSwuJHXhPrDckhds9l3eMFHCTFzzJTJRGlJErpgB0OKFFb3bC6Fx7TC7tBE08rOouIAvZiW00tyQOugnrd0qAtitZUwB63srYdUqIojqLAXuqBFA7GPKypym8-lnhEN8to9j797wE-Y3diryYqjOQh21st1_AcDbOVHbFdNVcjtn90fPblfOSPN0ZeA38D9kg4kw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAFAeWxUMBIPA4o6iaxY-8BoeVRbWnpAbXS3kzsTCDAJstmF9g_xW9kxkmWRki99Wo7iZ15fvZ4hrEnDoQEqSEAaVMEKCAD7SwC1xxCSBQMsZmiLY6Tyal4P5XTLfanuwtDYZWdTvSKOqsc7ZHvoRnUivBa-Gr-I6CqUXS62pXQaNjiENa_ELLVLw_eIn2fRtH-u5M3k6CtKhA4mYhlYGEkUhnBKEd-hTwWkYpwdi6UGbamcTSKMghTTSl8RZJa61yiCJak4ND7dzG-9xK7jIZ3SGBPTTcAL1TobXQXc3SyV6Pup7iiiOonKNQ8smf8fI2A_y3BGVPYD9M8Y_f2r7NrrcPKxw2H3WBbUN5kO-MSwfpszZ9xH0Lq9-Z32NdxjWDWFo6nrsj4gtLCQs0_VvPiZ-pSdGiDoqS2jM_W1bL6XTgEAbwoeZMABNt9zUBON08qRAYVfpTX39A0Ikbgs1WNU-B01lDfYqcX8ttvs-2yKuEu42KYQRTGVrg8EQqHJkkmdB6PMi2FFWrAwu4vG9dmOqeCG9-NRzw6MQ1lDFLGeMoYOWAvNs_Mmzwf545-TcTbjKQc3b6hWnw2rcgbayMrBAgXI2iFWFuNaDEHpYYS4tziS54T6Q1pEpyeS9sLEbhIysllxkoi8omR6QdstzcSNYDrd3fMY1oNVJt_8jJgjzfd9CRF1ZVQrZox6N-ihzZgdxpe2ywpVpSbUeAsdY8Le2vu95TFF5-fPKTTanSl750_r0fsyuTkw5E5Ojg-vM-uRl5OVBDKXba9XKzgAXp7S_vQixhnny5apv8CTP9pDg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ascorbic+acid+reduces+Ropivacaine-induced+myotoxicity+in+cultured+human+osteoporotic+skeletal+muscle+cells&rft.jtitle=BMC+musculoskeletal+disorders&rft.au=Scioli%2C+Maria+Giovanna&rft.au=Coniglione%2C+Filadelfo&rft.au=Greggi%2C+Chiara&rft.au=Evangelista%2C+Luca&rft.date=2023-07-15&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2474&rft.eissn=1471-2474&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12891-023-06702-5&rft.externalDocID=A757293778 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2474&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2474&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2474&client=summon |